Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts Post ContentrprxRead More You might also be interested in reading Joel Krueger: A Clarification. February 11, 2025 In Mainstream ← Previous post Next post →